В борьбе с туберкулезом достигнуты значительные прорывы, среди которых ускоренные и более точные методы диагностики и первые новые лекарственные средства за 50 л...т, однако сохраняется губительное отставание во внедрении этих нововведений в практику и обеспечения доступа к ним для уязвимых и социально ущемленных групп населения, в том числе заключенных, людей, живущих с ВИЧ, внутренних и внешних мигранты и наркопотребителей
more
Prepared as an outcome of ICMR Subcommittee on Non Hodgkin’s Lymphoma (High Grade) | This consensus document on management of non- hodgkin’s lymphoma – high grade summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molec...ular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
more
The intended purpose of this compendium is to provide program managers, organizations, and policy makers with a menu of indicators to better “know their HIV epidemic/know their response” from a gender perspective. The indicators in the compendium are all either part of existing indicators used i...n studies or by countries or have been adapted from existing indicators to address the intersection of gender and HIV. The indicators can be measured through existing data collection and information systems (e.g. routine program monitoring, surveys) in most country contexts, though some may require special studies or research.
more
2018 Controlling the HIV Epidemic Summit Geneva, 3-4 May 2018
3 May 2018
How concerned should we be about the new variants of SARS CoV 2 which cause COVID-19? Is it unusual for viruses to change and mutate? Do vaccines protect against these variants and what can you do to protect yourself? WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5
This paper reviews the effects of vertical responses to COVID-19 on health systems, services, and people’s access to and use of them in LMICs, where historic and ongoing under-investments heighten vulnerability to a multiplicity of health threats. We use the term ‘vertical response’ to describ...e decisions, measures and actions taken solely with the purpose of preventing and containing COVID-19, often without adequate consideration of how this affects the wider health system and pre-existing resource constraints.
more
If you have had COVID-19, should you still get vaccinated ? Why are we not vaccinating children under 16? WHO’s Chief Scientist Dr Soumya Swaminathan explains these and other vaccine related questions in Science in 5 this week.
How far apart should the doses of vaccines be? What if I miss my second dose? Can I get two doses from two different manufacturers? How was safety of vaccines ensured? WHO’s Chief Scientist, Dr Soumya Swaminathan explains in Science in 5.
As new variants emerge people are wondering if they should wait until a more efficacious vaccine is available or if they should go ahead and get vaccinated now? Answering your questions on COVID-19 vaccines and variants in this episode of Science in 5 is WHO's Dr Soumya Swaminathan.
If you have been wondering when you would receive your vaccine? Why you should get vaccinated and are concerned about what your are hearing about side effects, this episode of Science with 5 with WHO’s Chief Scientist Dr Soumya Swaminathan is for you.
April 19,2021
MEDBOX Issue Brief no.12
How much protection does the current batch of COVID-19 vaccines provide us? Would you need a booster shot for new variants? What does science and evidence tell us about mass gatherings and the spread of COVID-19?
WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5 this week.
What is the guidance for vaccination of women with breastfeeding infants, women who are pregnant or planning to get pregnant and women who are menstruating? What about vaccines and fertility? WHO’s Dr Soumya Swaminathan explains in Science in 5.
Why does WHO recommend at this time, in June 2021, that vaccinating children is not a priority? When would their vaccination be prioritized? How is safety of these vaccines ensured? WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5.
Do the current batch of approved vaccines protect us from the Delta variant? What is the level of protection? If you can still get infected even after being fully vaccinated, then why should we vaccinate? WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5.
Issue Brief no. 16. 20 Sept 2021.
Many studies have shown the effectiveness of vaccination against COVID-19 and that it protects against severe
illness. A high vaccination rate is needed to combat the pandemic worldwide. Due to misinformation and myths,
there is still a great hesitancy to vaccina...te . With this Issue Brief, we would like to present various myths and provide
you with educational materials on the respective topics for communication in the MEDBOX
more
11 May 2022
What are WHO's recommendations for COVID-19 vaccines and children? And what does the evidence say so far about the safety of these vaccines in children? And if you live in a country where this vaccination is not available for your kids, how can you keep them safe? WHO’s Dr Soumya Swa...minathan explains in Science in 5.
more
2023 will mark the 75th year of the World Health Organization. The world has achieved many public health milestones in these 75 years. In Science in 5 today we will take a look into the future - to understand what are the innovations we can expect and what will be some of our biggest challenges. Her...e to paint us a picture of what Health for All would look like in the future is WHO's Chief Scientist, Dr Soumya Swaminathan.
more
Canadian Journal of Microbiology 25 June 2021 https://doi.org/10.1139/cjm-2020-0572
The UK government hosted the Global Vaccine Summit on June 4, 2020 under the patronage of the Rt. Hon. Boris Johnson, Prime Minister of the United Kingdom of Great Britain and Northern Ireland. The meeting was held by videoconference in light of the ongoing COVID-19 pandemic. 2. The Summit brought... together more than 300 people, including 42 Heads of State and Government. 62 countries were represented, notably 14 Gavi implementing countries, all of the G7 nations and 19 governments of the G20. Eminent participants also included H.E. Antonio Guterres, Secretary-General of the United Nations; H.E. Moussa Faki Mahamat, Chairperson of the African Union Commission; H.E. Dr Tedros Adhanom Ghebreyesus, WHO Director-General; H.E. Henrietta Fore, UNICEF Executive Director; Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation; Ministers from implementing and donor countries; CEOs of vaccine manufacturing companies and private sector partners; leaders of UN and other international agencies; senior civil society representatives; and Gavi champions. A full list of the participants can be found in Annex.
more